1292 related articles for article (PubMed ID: 16439507)
21. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
[TBL] [Abstract][Full Text] [Related]
22. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
23. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
Andersen CY; Humaidan P; Ejdrup HB; Bungum L; Grøndahl ML; Westergaard LG
Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
[TBL] [Abstract][Full Text] [Related]
24. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
[TBL] [Abstract][Full Text] [Related]
25. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
Radesic B; Tremellen K
Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
[TBL] [Abstract][Full Text] [Related]
26. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
[TBL] [Abstract][Full Text] [Related]
27. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
28. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
29. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
30. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
31. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
32. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
[TBL] [Abstract][Full Text] [Related]
33. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
34. [Application of gonadotropin-releasing hormone agonist for triggering ovulation in high risk gonadotropin stimulating cycles of infertile polycystic ovary syndrome patients].
Dong H; Chen S; Xing F
Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):94-6. PubMed ID: 11263206
[TBL] [Abstract][Full Text] [Related]
35. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
[TBL] [Abstract][Full Text] [Related]
37. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
38. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
40. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]